Biomarkers are naturally occurring molecules that can be used as indicators of a normal biological process or a disease state. They play an essential role in cancer research, where immunohistochemical (IHC) detection of specific biomarkers is used to investigate the mechanisms underlying disease development and progression. A major advantage of using IHC to study cancer is that it provides visual context to a tumor and the surrounding tumor microenvironment (TME), often revealing unique insights that can help determine the most appropriate form of therapeutic intervention.
Accurately detecting biomarkers by IHC requires highly specific, rigorously validated antibody reagents. At CST®, we adhere to the Hallmarks of Antibody Validation, a set of complementary strategies for confirming the specificity, sensitivity, and functionality of an antibody in any given assay. By carefully tailoring how we validate our biomarker antibodies for IHC, we ensure results you can trust. This guide groups the most critical biomarkers for cancer research into seven categories to emphasize the value of studying multiple biomarker types in parallel to advance the understanding of cancer.
Click the filters to the left to explore Cancer Biomarkers for IHC by organ/tissue type or biomarker type, and download the Cancer Biomarkers for IHC eBook.
